ASND Stock Forecast: Ascendis Pharma A/S Price Predictions for 2026-2027

Last close, 20 Nov 2026
$253
−1.26% on the day

The 21 Wall Street analysts covering Ascendis Pharma A/S hold a median 12-month price target of $313 — +24.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$16.6B
Ticker Nerd rank
93/ 100
Median analyst target
$313
Analysts covering
21
Revenue$339.3M+114.7% y/y
Operating income$220.5M
Net income$207.0M
Free cash flow$270.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.2%
1M
+7.9%
YTD
+18.5%
1Y
+20.6%
From 52W high
−8.8%
From 52W low
+28.5%
$197
$277
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Ascendis Pharma A/S on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
93/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Value
98
Volatility
95
Growth
90
Momentum
81
Revisions
80
Issuance
76
Accruals
9

Quality (100): The business earns solid, repeatable profits on what it owns.

Accruals (9): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ASND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350Jan 26Apr 26Jul 26Oct 26ASNDHigh $354Median $313Low $272

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
20
Buy
1
Hold
0
Sell
$272
Low
$313
Median
$354
High

The green dot is the last close — the median target sits +24.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
16 Nov 2026BarclaysMaintainsOverweight$329 → $341
13 Nov 2026Canaccord GenuityMaintainsHold$268 → $274
13 Nov 2026Cantor FitzgeraldMaintainsOverweight$300 → $315
13 Nov 2026Evercore ISI GroupMaintainsOutperform$326 → $356
13 Nov 2026HC Wainwright & Co.MaintainsBuy$344 → $335
13 Nov 2026RBC CapitalReiteratesOutperform$290
13 Nov 2026TD CowenMaintainsBuy$341 → $352
13 Nov 2026UBSMaintainsBuy$269 → $315
13 Nov 2026Wells FargoMaintainsOverweight$326 → $330
26 Oct 2026CitigroupMaintainsBuy$360 → $330
15 Oct 2026UBSAssumesBuy$307 → $269
25 Sept 2026Cantor FitzgeraldReiteratesOverweight$300
15 Sept 2026Raymond JamesDowngradeOutperform—
2 Sept 2026OppenheimerMaintainsOutperform—
1 Sept 2026Morgan StanleyMaintainsOverweight—
1 Sept 2026WedbushReiteratesOutperform—
31 Aug 2026B of A SecuritiesMaintainsBuy—
31 Aug 2026HC Wainwright & Co.MaintainsBuy—
31 Aug 2026JefferiesMaintainsBuy—
31 Aug 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ASND.

Market Radar

This page is one stock. Monday covers all of them.

ASND appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ASND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Ascendis Pharma A/S returned +20.6% against +6.9% for the S&P 500, dividends included.

ASND vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26ASNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ASND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+9.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.6×

Cheaper than 52% of US stocks

Price / sales
13.8×

Cheaper than 10% of US stocks

Price / book
9.8×

Cheaper than 8% of US stocks

EV / EBITDA
42.5×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
91.8%

Higher than 97% of US stocks

Operating margin
30.9%

Higher than 88% of US stocks

Net margin
72.9%

Higher than 98% of US stocks

Returns & dividend
Return on equity
132.2%

Higher than 97% of US stocks

Return on assets
13.0%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ascendis Pharma A/S has a market value of $16.6B and an enterprise value of $17.6B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 114.7% year on year.

  • Net income over the same four quarters: $741.8M, a 70.8% net margin.

  • Diluted earnings per share, trailing twelve months: $11.03.

  • Free cash flow in the twelve months to 30 June 2026: $335.1M.

  • Ascendis Pharma A/S spent $103.4M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 65.7M.

  • Trailing P/E: 16.6×; forward P/E: 20.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ascendis Pharma A/S employs 1,189 people — $881K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

ASND and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASNDAscendis Pharma A/S$16.6B93
EXELExelixis, Inc.$15.8B100
BBIOBridgeBio Pharma, Inc.$14.7B80
JAZZJazz Pharmaceuticals Plc$14.4B95
ALNYAlnylam Pharmaceuticals, Inc.$19.3B58
INCYIncyte Corp.$22.9B89
BMRNBioMarin Pharmaceutical, Inc.$11.7B51

Take a look at ASND’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Ascendis Pharma A/S — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ASND

What is the ASND stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Ascendis Pharma A/S have a median 12-month price target of $313, with estimates ranging from $272 to $354. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASND stock a buy right now?

Of the 21 analysts covering Ascendis Pharma A/S, 20 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ascendis Pharma A/S 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASND?

As at 21 Nov 2026, Ascendis Pharma A/S ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will ASND stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +24.0% from the last close, and Ticker Nerd's factor model ranks Ascendis Pharma A/S 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASND stock forecast for 2030?

No analyst covering Ascendis Pharma A/S publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $272 to $354 over the next 12 months.

How has ASND stock performed over the past year?

Ascendis Pharma A/S returned +20.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs.

Company

About Ascendis Pharma A/S.

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.

CEO Mr. Jan Moller Mikkelsen · 1,189 employees · Denmark · https://ascendispharma.com